Xiaoming Hou

Lanzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Integrated bulk RNA-seq and scRNA-seq identification of a novel "PET-SPI1-MYL9" transcriptional axis in lung adenocarcinoma driven by polyethylene terephthalate exposure.

Integrated bulk RNA-seq and scRNA-seq identification of a novel "PET-SPI1-MYL9" transcriptional axis in lung adenocarcinoma driven by polyethylene terephthalate exposure.

Journal: Translational cancer research

Published: November 25, 2025

Aumolertinib Versus Osimertinib as First-Line Treatment for EGFR-Mutant Non-Small Cell Lung Cancer: A Retrospective Real-World Multicenter Study.

Aumolertinib Versus Osimertinib as First-Line Treatment for EGFR-Mutant Non-Small Cell Lung Cancer: A Retrospective Real-World Multicenter Study.

Journal: International journal of cancer

Published: November 22, 2025

Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): prespecified interim analysis of a randomized, phase III clinical trial.

Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): prespecified interim analysis of a randomized, phase III clinical trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: November 05, 2025

Spotlights on ubiquitin-specific proteases in lung cancer: from multifaceted pathophysiological mechanisms to potential therapeutic targets.

Spotlights on ubiquitin-specific proteases in lung cancer: from multifaceted pathophysiological mechanisms to potential therapeutic targets.

Journal: PeerJ

Published: July 24, 2025

Early liver injury risk assessment in critically injured trauma patients using intelligent calculation method: a retrospective study

Early liver injury risk assessment in critically injured trauma patients using intelligent calculation method: a retrospective study

Journal: Zhonghua wei zhong bing ji jiu yi xue

Published: February 28, 2025

pH-Activated Nanoplatform Derived from M1 Macrophages' Exosomes for Photodynamic and Ferroptosis Synergistic Therapy to Augment Cancer Immunotherapy.

pH-Activated Nanoplatform Derived from M1 Macrophages' Exosomes for Photodynamic and Ferroptosis Synergistic Therapy to Augment Cancer Immunotherapy.

Journal: Biomaterials research

Published: November 08, 2024

Prognostic aging gene-based score for colorectal cancer: unveiling links to drug resistance, mutation burden, and personalized treatment strategies.

Prognostic aging gene-based score for colorectal cancer: unveiling links to drug resistance, mutation burden, and personalized treatment strategies.

Journal: Discover oncology

Published: August 13, 2024

PD-L1 expression and its association with clinicopathological and computed tomography features in surgically resected non-small cell lung cancer: a retrospective cohort study.

PD-L1 expression and its association with clinicopathological and computed tomography features in surgically resected non-small cell lung cancer: a retrospective cohort study.

Journal: Scientific reports

Published: July 10, 2024

Acidity-activatable dynamic hybrid nanoplatforms derived from extracellular vesicles of M1 macrophages enhance cancer immunotherapy through synergistic triple immunotherapy.

Acidity-activatable dynamic hybrid nanoplatforms derived from extracellular vesicles of M1 macrophages enhance cancer immunotherapy through synergistic triple immunotherapy.

Journal: Journal of nanobiotechnology

Published: March 11, 2024

A randomized phase 2 study of HLX22 plus trastuzumab biosimilar HLX02 and XELOX as first-line therapy for HER2-positive advanced gastric cancer.

A randomized phase 2 study of HLX22 plus trastuzumab biosimilar HLX02 and XELOX as first-line therapy for HER2-positive advanced gastric cancer.

Journal: Med (New York, N.Y.)

Published: February 05, 2024

Value of dynamic contrast-enhanced magnetic resonance imaging in combination with mammography for screening early-stage breast cancer.

Value of dynamic contrast-enhanced magnetic resonance imaging in combination with mammography for screening early-stage breast cancer.

Journal: African health sciences

Published: January 15, 2024

Anlotinib in Chinese patients aged ≥70 years with advanced non-squamous non-small cell lung cancer without prior chemotherapy: a multicenter, single-arm pilot trial.

Anlotinib in Chinese patients aged ≥70 years with advanced non-squamous non-small cell lung cancer without prior chemotherapy: a multicenter, single-arm pilot trial.

Journal: Frontiers in oncology

Published: November 08, 2023

Showing 1-12 of 29

Last Updated: 09/26/2026